Dr. Reddy’s shares in focus as EC clears biosimilar used to treat Osteoporosis

Dr. Reddy’s Laboratories said that the European Commission (EC) has granted marketing authorisation for AVT03, a biosimilar of Prolia® (denosumab) and Xgeva® (denosumab).

Leave a Reply

Your email address will not be published. Required fields are marked *